Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [1];  [1];  [1];  [1];  [2];  [1]
  1. Georgia State Univ., Atlanta, GA (United States)
  2. Purdue Univ., West Lafayette, IN (United States)
+ Show Author Affiliations
HIV-1 protease inhibitors are effective in HIV/AIDS therapy, although drug resistance is a severe problem. This study examines the effects of four investigational inhibitors against HIV-1 protease with drug resistant mutations of V32I, I47V and V82I (PRTri) that model the inhibitor-binding site of HIV-2 protease. These inhibitors contain diverse chemical modifications on the darunavir scaffold and form new interactions with wild type protease, however, the measured inhibition constants for PRTri mutant range from 17 to 40 nM or significantly worse than picomolar values reported for wild type enzyme. The X-ray crystal structure of PRTri mutant in complex with inhibitor 1 at 1.5 Å resolution shows minor changes in interactions with inhibitor compared with the corresponding wild type PR complex. Instead, the basic amine at P2 of inhibitor together with mutation V82I induces two alternate conformations for the side chain of Arg8 with new interactions with inhibitor and Leu10. Hence, inhibition is influenced by small coordinated changes in hydrophobic interactions.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Basic Energy Sciences (BES)
Contributing Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Grant/Contract Number:
W-31109-ENG-38
OSTI ID:
1531006
Alternate ID(s):
OSTI ID: 1702259
Journal Information:
Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 3 Vol. 514; ISSN 0006-291X
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (35)

Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors journal September 2010
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors journal January 2012
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease journal December 2009
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: Relevance to drug resistance: Characterization of Group N HIV-1 Protease journal September 2010
Estimating KI values for tight binding inhibitors from dose-response plots journal September 1995
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments journal April 2013
Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection journal February 2014
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors journal March 2012
Implications of HIV diversity for the HIV-1 pandemic journal May 2013
Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir journal August 2008
Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Protease journal December 2008
HIV-1 drug resistance and resistance testing journal December 2016
HIV-1 protease inhibitors: effects on HIV-2 replication and resistance journal January 2008
Retroviral proteases and their roles in virion maturation journal May 2015
Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Studies journal August 2015
Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease journal September 2018
HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements journal March 2012
Influence of Flanking Sequences on the Dimer Stability of Human Immunodeficiency Virus Type 1 Protease † journal January 1996
Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease journal January 2013
Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies journal August 2013
Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease journal October 2008
Drug resistance mechanisms of three mutations V32I, I47V and V82I in HIV-1 protease toward inhibitors probed by molecular dynamics simulations and binding free energy predictions journal January 2016
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease journal July 1999
The Protein Data Bank journal January 2000
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy journal January 1999
Phaser crystallographic software journal July 2007
Features and development of Coot journal March 2010
Overview of the CCP 4 suite and current developments journal March 2011
Refinement of Macromolecular Structures by the Maximum-Likelihood Method journal May 1997
Crystal structure refinement with SHELXL journal January 2015
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters: HIV protease mutants altering hydrophobic clusters journal August 2010
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro journal February 2013
A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property In Vitro journal February 2015
HIV-1 Protease: Structural Perspectives on Drug Resistance journal December 2009

Cited By (1)

Highly drug‐resistant HIV‐1 protease reveals decreased intra‐subunit interactions due to clusters of mutations journal January 2020

Similar Records

Potent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1;#8242;-Pyrrolidinone Ring
Journal Article · Tue Nov 13 23:00:00 EST 2012 · J. Med. Chem. · OSTI ID:1047901
Room temperature neutron crystallography of drug resistant HIV-1 protease uncovers limitations of X-ray structural analysis at 100K
Journal Article · Mon Feb 13 19:00:00 EST 2017 · Journal of Medicinal Chemistry · OSTI ID:1361359
HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics
Journal Article · Wed Aug 31 20:00:00 EDT 2022 · Journal of Molecular Graphics and Modelling · OSTI ID:1887649

Related Subjects

60 APPLIED LIFE SCIENCES
Antiviral inhibitors
Drug resistance
HIV-1 protease
X-ray crystallography